Dana Pop, Adela-Viviana Sitar-Tăut, Lucia Procopciuc, Mirela Cebanu, M. Zdrenghea and D. Zdrenghea
1. NGUYEN G, MULLER DN. The biology of the (pro) renin receptor. J Am Soc Nephrol. 2010; 21(1):18-23.
2. SCHALEKAMP MA, DERKX FH, DEINUM J, DANSER AJ. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J Hypertens. 2008; 26(5):928-937. Review.
3. VOLPE M, BATTISTONI A, CHIN D, RUBATTU S, TOCCI G. Renin as a biomarker of cardiovascular disease in clinical practice. Nutr Metab Cardiovasc Dis. 2012; 22 (4):312-317.
4. DICKSTEIN K, COHEN-SOLAL A
Nebojsa Tasic, Danijela Tasic, Dalibor Dragisic and Miroslav Mitrovic
1. Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, Hollenberg NK. Non-modulation as an intermediate phenotype in essential hypertension. Hypertension. 1992 Dec;20(6):788-96.
2. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH. On the renal basis of essential hypertension. Nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. Kidney Int 1988;34(Supp1 25):S64-S7.
-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456-1462.
8. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.Ann Intern Med. 2008; 148:30-48.
9. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003; 63:1499-1507.
10. Andersen NH
Zbigniew Heleniak, Zbigniew Zdrojewski, Piotr Wisniewski, Leszek Bieniaszewski, Boleslaw Rutkowski and Alicja Debska-Slizien
(ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit ., 15, RA91-101, 2009.
5. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia , 32, 219-226, 1989.
6. Fliser D. et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol ., 16, 2456-2461, 2005.
7. Fujii H. et al. Renin-Angiotensin System Inhibitors Reduce Serum Asymmetric
Achard V, Boullu-Ciocca S, Desbriere R, Nguyen G, Grino M. Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol 292, R274–282, 2007.
Achard V, Tassistro V, Boullu-Ciocca S, Grino M. Expression and nutritional regulation of the (pro)renin receptor in rat visceral adipose tissue. J Endocrinol Invest 34, 840–846, 2011.
Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme
hypertension. Antihypertensive drugs such as thiazide diuretics and β-blockers adversely affect glucose metabolism and increase the risk of developing type-2 diabetes [ 3 - 6 ] , though this has been disputed [ 7 - 11 ] . On the other hand, drugs that interfere with the renin–angiotensin system (RAS) improve insulin sensitivity, produce a significant decline of albuminuria, induce a drop of the pathological glomerular hyperfiltration, and reduce the incidence of new-onset diabetes [ 12 - 17 ] . Therefore, the initial selection of antihypertensive therapy for obese
Abdullah Arpacı, Meral Urhan-Kucuk, Aysegul Bayramoglu, Halil İbrahim Guler, Hasret Ecevit, Arif Suner and Sevim Karakaş-Celik
10. Jiang X, Sheng H, Li J, Xun P, Cheng Y, Huang J, et al. Association between renin-angiotensin system gene polymorphism and essential hypertension: a community-based study. J Hum Hypertens. 2009; 23(3):176-81. DOI: 10.1038/jhh.2008.123
11. Zhao J, Qin X, Li S, Zeng Z. Association between the ACE I/D polymorphism and risk of ischemic stroke: an updated meta-analysis of 47,026 subjects from 105 case-control studies. J Neurol Sci. 2014; 345(1-2):37-47. DOI: 10.1016/j.jns.2014.07.023
12. Niu W, Qi Y, Hou S, Zhai X, Zhou W, Qiu C
Samia Abd El-Moneim Ebied, Nadia Aly Sadek, Nadia El-Sayed Zaki, Samir Ali Abd El- Kaream and Heba Khafagui Ahmed El Kashif
There is increasing evidence that angiotensin II (Ang II), a major regulator of blood pressure and cardiovascular homeostasis, is involved in the regulation of cell proliferation, angiogenesis, inflammation and tissue remodeling, which suggests that this peptide might also play a role in cancer [ 1 ]. The renin-angiotensin system (RAS) has been characterized extensively in hypertension and atherosclerosis, but recently its relevance to the fields of oncology and hematology are being studied [ 2 , 3 ].
The RAS pathway mediates its effect
Pană Camelia, Fâșie Dragoș, Voinea Claudia and Tuță Liliana Ana
. 2011 Jan;7(1):55. DOI: 10.1038/nrneph.2010.158
16. Kao C-C, Wu V-C, Kuo C-C, Lin Y-H, Hu Y-H, Tsai Y-C, et al. Delayed diagnosis of primary aldosteronism in patients with autosomal dominant polycystic kidney diseases. Journal of the Renin-Angiotensin-Aldosterone System. 2013;14(2):167-73. DOI: 10.1177/1470320312452767
17. Torres VE, Young Jr WF. Offord KP. Hattery RR: Association of hypokalemia, aldosteronism, and renal cysts. N EngI J Med. 1990;322:345-51. doi:10.1056/NEJM199002083220601
18. Torres VE, Donovan KA, Scicli G, Holley KE, Thibodeau SN